SCIENTIFIC publications

Advanced search
/cun/en/investigacion/publicaciones-cientificas/areaMain/02

  • EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks

    Gouya L (1), Ventura P (2), Balwani M (3), Bissell DM (4), Rees DC (5), Stölzel U (6), Phillips JD (7), Kauppinen R (8), Langendonk JG (9), Desnick RJ (3), Deybach JC (1), Bonkovsky HL (10), Parker C (7), Naik H (3), Badminton M (11), Stein PE (5), Minder E (12), Windyga J (13), Bruha R (14), Cappellini MD (15), Sardh E (16), Harper P (16), Sandberg S (17), Aarsand AK (17), Andersen J (17), Alegre F (18), Ivanova A (19), Talbi N (20), Chan A (21), Querbes W (21), Ko J (21), Penz C (21), Liu S (21), Lin T (21), Simon A (21), Anderson KE (22).

    (1) Centre de Référence Maladies Rares Porphyries, Colombes, France.
    (2) Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy.
    (3) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (4) University of California, San Francisco, CA, USA.
    (5) King's College Hospital, King's College London, London, UK.
    (6) Klinikum Chemnitz Porphyria Center, Chemnitz, Germany.
    (7) University of Utah, Salt Lake City, UT, USA.
    (8) University Hospital of Helsinki, Helsinki, Finland.
    (9) Porphyria Center, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
    (10) Section on Gastroenterology & Hepatology, Wake Forest University/NC Baptist Medical Center, Winston-Salem, NC, USA.
    (11) University Hospital of Wales, Cardiff, UK.
    (12) Stadtspital Triemli, Zentrallabor, Zurich, Switzerland.
    (13) Department of Hemostatic Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
    (14) 4th internal clinic, General University Hospital, Charles University, Prague, Czech republic.
    (15) University of Milan, Fondazione IRCCS, Ca Granda, Milan, Italy.
    (16) Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
    (17) Norwegian Porphyria Centre, Haukeland University Hospital, Bergen, Norway.
    (18) Clinica Universidad de Navarra, Navarra, Spain.
    (19) St. Ivan Rilski U Hospital, Sofia, Bulgaria.
    (20) Laboratory of Excellence GR-Ex, University of Paris, Paris, France.
    (21) Alnylam Pharmaceuticals, Cambridge, MA, USA.
    (22) University of Texas Medical Branch, Galveston, TX, USA

    Hepatology 12 SEPTEMBER 2019

  • Oscillopsia in Bilateral Vestibular Hypofunction: Not Only Gain But Saccades Too

    Batuecas-Caletrio A (1), Trinidad-Ruiz G (2), Rey-Martinez J (3), Matiño-Soler E (4), Martin Sanz E (5), Perez Fernandez N (6).

    (1) Otoneurology Unit, ENT De partment, University Hospital of Salamanca, IBSAL, Salamanca, Spain.
    (2 )Department of Otolaryngology, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.
    (3) Otolaryngology Unit, ORL Gipu zkoa, Clínica Quirón, San Sebastián, Spain.
    (4) Department of Otolaryngology, Hospital General de Catalunya, Sant Cugat del Vallés, Barcelona, Spain.
    (5) Department of Otolaryngology, Hospital Universitario De Getafe, Getafe, Spain.
    (6) Department of Otolaryngology, Clínica Universidad De Navarra, Madrid, Spain.

    Ear and Hearing 10 SEPTEMBER 2019

  • Tolerogenic dendritic cell-based treatment for multiple sclerosis

    Willekens B# (1,2), Presas-Rodríguez S# (3,4), Mansilla MJ (5,6), Derdelinckx J (1,2), Lee WP (7), Nijs G (7), De Laere M (2), Wens I (2), Cras P (1), Parizel P (8), Van Hecke W (9), Ribbens A (9), Billiet T (9), Adams G (10), Couttenye MM 11, Navarro-Barriuso J (5,6), Teniente-Serra A (5,6), Quirant-Sánchez B (5,6), Lopez-Diaz de Cerio A (12,13), Inogés S (12,13), Prosper F (12,14), Kip A (15), Verheij H (15), Gross CC (16,17), Wiendl H (16,17), Van Ham MS (18,19), Ten Brinke A (18,19), Barriocanal AM (20,21), Massuet-Vilamajó A (22), Hens N (23,24), Berneman Z (2,7), Martínez-Cáceres E (5), Cools N# (25,7), Ramo-Tello C# (26); RESTORE consortium.

    (1) Department of Neurology, University Hospital Antwerp, Edegem, Belgium.
    (2) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (3) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (4) Department of Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, Spain.
    (5) Division of Immunology, LCMN, Hospital Universitario Germans Trias i Pujol and Research Institute, Badalona, Spain.
    (6) Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
    (7) Center for Cell Therapy and Regenerative Medicine, University Hospital Antwerp, Edegem, Belgium.
    (8) Department of Radiology, University Hospital Antwerp, Edegem, Belgium.
    (9) Icometrix NV, Leuven, Belgium.
    (10) C-Clear Partners, Mortsel, Belgium.
    (11) Department of Nephrology, University Hospital Antwerp, Edegem, Belgium.
    (12) Haematology-Cell Therapy Area, clinica universidad de navarra, Pamplona, Spain.
    (13) Immunology and Immunotherapy Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (14) Program of Haematology-Oncology, CIMA, Universidad de Navarra, Pamplona, Spain.
    (15) Lygature, Utrecht, The Netherlands.
    (16) Department of Neurology, University Hospital Munster, Munster, Germany.
    (17) Department of Neurology, University of Munster, Munster, Germany.
    (18) Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
    (19) Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    (20) Clinical Research Polyvalent Unit, Clinial Trial Unit-Spanish Clinical Research Network, Germans Trias i Pujol Health Sciences Research Institute, Badalona, Spain.
    (21) Department of Pharmacology, Therapeutic and Toxicology, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
    (22) Institut de Diagnòstic per la Imatge, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
    (23) Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Universiteit Hasselt, Hasselt, Belgium.
    (24) Centre for Health Economic Research and Modelling Infectious Diseases, Vaccine & Infectious Disease Institute (VAXINFECTIO) & Center for Statistics, University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium.
    (25) Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp Faculty of Medicine and Health Sciences, Wilrijk, Belgium
    (26) Multiple Sclerosis Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    # Contributed equally

    BMJ Open 09 SEPTEMBER 2019

  • Transforming Breast Cancer Together: European elections manifesto 2019 seizing the opportunities for breast cancer patients

    Cardoso F (1), Bușoi CS (2), Cattaneo I (3), Decise D (3), Cardone A (4), Filicevas A (4), Gentile E (5), Wierinck L (5), Knox S (6, Sebastiani S (7), Terrasanta C (7), Ujupan S (8), Ventura R (9), Wilson B (10), Rubio IT (11).

    (1) European School of Oncology (ESO) and Advanced Breast Cancer Global Alliance (ABC Global Alliance), Champalimaud Clinical Centre / Champalimaud Foundation, Lisbon, Portugal.
    (2) Member of the European Parliament, Brussels, Belgium.
    (3) Novartis, Origgio, Italy.
    (4) European Cancer Patient Coalition, Brussels, Belgium.
    (5) Former Member of the European Parliament, Brussels, Belgium.
    (6) Europa Donna- the European Breast Cancer Coalition, Milan, Italy.
    (7) Helsinn Healthcare SA, Lugano, Switzerland.
    (8) Eli Lilly and Company, Brussels, Belgium.
    (9) European School of Oncology (ESO), Advanced Breast Cancer Global Alliance (ABC Global Alliance), Bellinzona, Switzerland.
    (10) Working with Cancer, London, United Kingdom.
    (11) European Society of Breast Cancer Specialists (EUSOMA), European Society of Surgical Oncology (ESSO), Clinica Universidad de Navarra, Madrid, Spain.

    Breast 07 SEPTEMBER 2019

  • Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer

    Ponz-Sarvise M (1), Corbo V (2), Tiriac H (3), Engle DD (4), Frese KK (5), Oni TE (6), Hwang CI (3), Öhlund D (7), Chio IIC (8), Baker LA (3), Filippini D (3), Wright K (3), Bapiro TE (9), Huang PS (10), Smith PD (11), Yu KH (12), Jodrell DI (13), Park Y (3), Tuveson DA (14).

    (1) Medical Oncology, Clinica Universidad de Navarra, Universidad de Navarra.
    (2) Diagnostics and Public Health, ARC-Net Research Centre, University and Hospital Trust of Verona.
    (3) Cold Spring Harbor Laboratory.
    (4) Regulatory Biology Laboratory, Salk Institute for Biological Studies.
    (5) Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute.
    (6) Cancer Center, Cold Spring Harbor Laboratory.
    (7) Wallenberg Centre for Molecular Medicine, Umeå University.
    (8) Genetics and Development, Columbia University.
    (9) CRUK Cambridge Institute, University of Cambridge.
    (10) G&A, Cygnal Therapeutics.
    (11) Oncology Bioscience, AstraZeneca (United Kingdom).
    (12) Medicine, Memorial Sloan Kettering Cancer Center.
    (13) Cancer Research UK Cambridge Institute, University of Cambridge.
    (14) Cold Spring Harbor Laboratory

    Clinical Cancer Research 06 SEPTEMBER 2019

Anterior 1 2 3 4 5 ... 970 Next

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra